Contrasting with these studies of anti-CTLA-4 antibody-mediated inhibitory effects on T-cell activation were clear demonstrations of anti-tumour activity in several mouse models, supporting the potential for treating patients with anti-CTLA-4 antibodies [49–53]. Here, CTLA4 is linked to neoplasm.